218 A case of Toxic Epidermal Necrolysis secondary to combination Ipilimumab and Nivolumab therapy for Pleural Mesothelioma, successfully treated with Ruxolitinib
We present the case of a patient who developed Toxic Epidermal Necrolysis (TEN) as the primary feature of a multi-system autoimmune syndrome following combination ipilimumab and nivolumab for mesothelioma, successfully treated with Ruxolitinib. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Judy Tabbakh, Racha Kussaibati, Francesca Kinsella, Gary Middleton, Victoria Kunene, Sawsan Elsheikh, Claudia Roberts, Darren Lewis, Rachel Powell, Ser-Ling Chua, Shobhit Baijal Tags: Case Reports Source Type: research
214 Rowell Syndrome as a Paraneoplastic Manifestation of Metastatic Mesothelioma
A 60-year-old male presented in 2021 with pulmonary metastatic epitheloid mesothelioma. Notable history included psoriasis and T4aN2bM0 sarcomatoid squamous-cell-carcinoma of the oral-cavity treated with palliative radiotherapy. Due to an extraordinary response to radiotherapy, Head and Neck Multidisciplinary-Team-Meeting re-review felt a lymphomatoid process more likely. For mesothelioma, he completed 4 cycles of palliative pemetrexed/ carboplatin chemotherapy with partial-response but then stopped due to bone-marrow toxicity. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Helen-Cara Younan, Eunice Xing, Hend Owaidat, Polyanna Leite, Danielle Power, Waleed Mohammed, Joanne Evans Tags: Case Reports Source Type: research
211 The impact of the flu vaccine on fluid volumes in a patient with mesothelioma
A 78-year-old woman with end stage chronic obstructive pulmonary disease and a right pleural mesothelioma had an indwelling pleural catheter (IPC) in situ for control of her malignant effusion. She was for best supportive care. Serous, yellow fluid was drained 2 –3 times a week, volumes averaged 150–200 mls. The patient underwent influenza vaccination as part of yearly routine primary care. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Leah Taylor, Helen Wallace, Avinash Aujayeb Tags: Case Reports Source Type: research
208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma
Mesothelioma is a rare cancer caused by exposure to asbestos typically affecting the pleura or pericardium. Prognosis remains dismal yet targeted therapies are lacking. Advances have revealed a preponderance of tumour suppressors in mesothelioma, which may present new opportunities to develop treatments. The SELECTmeso trial platform, coordinated by the Cancer Research UK Southampton Clinical Trials Unit, has been developed to leverage new insights into synthetic lethal biology to improve treatment outcomes. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Kayleigh Hill, Dean Fennell, Anna Song, Robin Wickens, Judith Cave, Andrea Corkhill, Jens Hahne, Michelle Lattimore, Peter Wells-Jordan, Nada Nusrat, Sean Dulloo, Charlotte Poile, Gareth Griffiths Tags: Trials in progress Source Type: research
75 Real world toxicity data for the use of ipilimumab plus nivolumab in malignant mesothelioma
Ipilimumab plus nivolumab has been licensed to treat malignant mesothelioma (MM) in England since 2020. Here we present the real world toxicity outcomes for MM patients receiving this first line doublet immunotherapy regimen at a single UK centre. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: McGrath Harriet, Kaiser Anam, Cienne Morton, Spyridon Gennatas, Sharmistha Ghosh, Eleni Karapanagiotou, Alexandras Georgiou, James Spicer Tags: Mesothelioma Source Type: research
74 Is Age A Thing? Accessing Treatment for Pleural Mesothelioma
Since February 2018, Royal Papworth Hospital (RPH) has hosted weekly Regional Mesothelioma Multidisciplinary Team (MDT) Meetings. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Kate Slaven, David Gilligan Tags: Mesothelioma Source Type: research
73 Ipilimumab and Nivolumab for mesothelioma: a real-world UK tertiary centre experience
Ipilimumab and Nivolumab (IPI/NIVO) has been reimbursed as 1st line treatment for patients with mesothelioma in the UK since July 2022 based on the CHECKMATE 743 study, which demonstrated survival benefit of IPI/NIVO over chemotherapy, largely driven by improvement in non-epithelioid subgroup. Toxicity profile was consistent with use of this regimen in other malignancies. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: David John McMahon, Trisha Patel, Rehab Ahmed, Alexius John, Elizabeth Cartwright, Thubeena Manickavasagar, Charlotte Milner-Watts, Abu Taher, Cheryl Estall, Nadia Yousaf, Sanjay Popat, Mary O Brien, Michael Davidson, Jaishree Bhosle, Anna Minchom, Nadza Tags: Mesothelioma Source Type: research
72 Audit of Oxford University Hospitals Mesothelioma service
We present the initial results of analysis of patients diagnosed and treated for mesothelioma at a tertiary cancer centre (Oxford University Hospitals NHS Foundation Trust, OUH). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Sarah Briggs, Alguili Elsheikh, Charlotte Buckle, Najib Rahman, John M Wrightson, Nicholas Coupe Tags: Mesothelioma Source Type: research
71 Mesothelioma incidence, presentation and treatment in the northeast of England
The evolution of mesothelioma care in the North East of England pre- and post-pandemic is not known. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Lim Cheng Hong, Leah Taylor, Helen Wallace, Avinash Aujayeb Tags: Mesothelioma Source Type: research
70 Information needs of families/friends supporting people living with mesothelioma: findings from a UK survey
Families/friends supporting people living with mesothelioma have complex information needs, both in making sense of the diagnosis, treatment options, and in providing support/care across the trajectory. The Mesothelioma UK Research Centre developed a research project to explore the support needs of family/friends. A key aspect was to identify the information needs. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Sarah Hargreaves, Clare Gardiner, Angela Tod Tags: Mesothelioma Source Type: research
